Stay updated with breaking news from Sandra Aung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The administration of ARX517 at 3.4 mg/kg did not result in any dose-limiting toxicities or serious adverse effects in patients with metastatic castration-resistant prostate cancer enrolled in cohort 9 of the phase 1/2 APEX-01 trial.
The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.
SAN DIEGO - Ambrx Biopharma Inc., Ambrx , today announced that the U.S. Food and Drug Administration has granted Fast Track designation to Ambrx's proprietary anti-PSMA antibody-drug conjugate ...
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Developm...